Arxo Findings Register · Arxo Law

ARXO-2026-0311 · Reported

amino acids with electrolytes in dextrose (5/20 formulation): Table 1 and Table 2 give different instructions for one patient

Table 1 reads “3.2 to 8”. Table 2 reads “1.25”. Example: For a 70 kg adult, the top of the Table 1 dextrose range (8 g/kg/day) needs about 2800 mL a day; the Table 2 maximum infusion rate of 1.25 mL/kg/hour allows about 2100 mL a day (6 g/kg/day). The same text is in 2 labels from 2 labelers in the DailyMed release of 29 October 2026.

Consequence

Potential effect on a prescribing decision: low; careful reading of the whole label usually resolves it. Arxo does not say which instruction is correct and gives no dose.

Jurisdiction
United States — federal
Act
amino acids with electrolytes in dextrose (5/20 formulation) prescribing information (SPL set ID 8469d6fb-d6ef-476f-8cc3-0905192de0a8)
Place
Table 1 and Table 2
Record
Discrepancy
Class
Text of the act
Where it arose
The text of the act
Arxo's conclusion
Confirmed
Official text
Unchanged at last check
Last checked
2026-10-31

Evidence

Pair of quotations. Quotations are verbatim from the official material; translations are ours and marked.

3.2 to 8
Official publication · Prescribing information, Baxter Healthcare Company, SPL set ID 8469d6fb-d6ef-476f-8cc3-0905192de0a8, version 17 (DailyMed) · Table 1 · version 17 · retrieved 2026-10-29 · SHA-256 05ab76f8671530a7ee2cf2e79d5c39ae27ec134ae44be525bd22fa3652d574f5 · copy
1.25
Official publication · Prescribing information, Baxter Healthcare Company, SPL set ID 8469d6fb-d6ef-476f-8cc3-0905192de0a8, version 17 (DailyMed) · Table 2 · version 17 · retrieved 2026-10-29 · SHA-256 05ab76f8671530a7ee2cf2e79d5c39ae27ec134ae44be525bd22fa3652d574f5 · copy

How to check it without Arxo's tools

  1. Open Prescribing information, Baxter Healthcare Company, SPL set ID 8469d6fb-d6ef-476f-8cc3-0905192de0a8, version 17 (DailyMed) and find Table 1; Table 2. Compare the text with the quotation above. A copy is kept in this register: 05ab76f8671530a7-8469d6fb-d6ef-476f-8cc3-0905192de0a8-v17.xml (SHA-256 05ab76f8671530a7ee2cf2e79d5c39ae27ec134ae44be525bd22fa3652d574f5, copy of the official file).
  2. The finding holds if the quoted passages read as shown and the comparison gives the result stated at the top of this page. If it does not, write to us with the record ID.

How this finding was made

AI agents read the labels, compared their parts and, where marked, ran the example patient through executable rules; an AI agent then read each place in full, with tables and footnotes, and confirmed it. No clinician has assessed these places. A person at Arxo approved publication (2026-10-31).

Responsible institutions

Reported to

DateInstitutionChannelReference
2026-10-31Baxter Healthcare Corporatione-mail
2026-10-31U.S. Food and Drug Administration, Center for Drug Evaluation and Researche-mail

Responses

No response recorded.

History

  1. 2026-10-31Confirmed by Arxo
  2. 2026-10-31Reported to Baxter Healthcare Corporation (e-mail)
  3. 2026-10-31Reported to U.S. Food and Drug Administration, Center for Drug Evaluation and Research (e-mail)

Cite this record

Arxo Law, Arxo Findings Register, ARXO-2026-0311, https://arxo.io/findings/ARXO-2026-0311/ (status as of 2026-10-31). Data: ARXO-2026-0311.json.